Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01326377
A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk
Professor of Medicine (Hematology), Emeritus
Professor of Medicine (Hematology)
- Diagnosis of MDS confirmed within 2 weeks prior to study entry according to the World
Health Organization (WHO) Criteria or the French-American-British (FAB)
- Trisomy 8 cytogenetics (simple or combined to other karyotypes) or patient classified
as Intermediate-1 with bone marrow blasts equal to or greater than 5%, Intermediate-2
or High Risk MDS according to the IPSS score, or Patients with peripheral blood blasts
equal to or greater than 5%.
- At least one cytopenia (Absolute Neutrophil Count < 1800/µl or Platelet Count
<100,000/µl or Hemoglobin < 10 g/dL).
- Failure of, or insufficient response to Azacytidine or Decitabine administered for 4
to 6 cycles in patients classified as Intermediate-2 or High risk or to Erythrocyte
stimulating agents (failure or insufficient response defined as transfusion dependence
or Hemoglobin remaining below 10 g/dl) in Low or Intermediate-1 Risk Trisomy 8
- Failed to respond to, relapsed following, or opted not to participate in bone marrow
- Off all other treatments for MDS (including filgrastim (G-CSF) and erythropoietin) for
at least four weeks. As an exception, filgrastim (G-CSF) can be used before, during
and after the protocol treatment for patients with documented febrile neutropenia (<
- ECOG Performance Status 0, 1 or 2.
- Willing to adhere to the prohibitions and restrictions specified in this protocol.
- Patient (or his/her legally authorized representative) must have signed an informed
consent document indicating that he/she understands the purpose of and procedures
required for the study and is willing to participate in the study.
- Anemia due to factors other than MDS (including hemolysis or gastrointestinal
- Hypoplastic MDS (cellularity <10%).
- Any active malignancy within the past year except basal cell or squamous cell skin
cancer or carcinoma in situ of the cervix or breast.
- History of HIV-1 seropositivity.
- Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
heart failure, unstable angina pectoris or cardiac arrhythmia.
- Active infection not adequately responding to appropriate therapy.
- Total bilirubin > 1.5 mg/dL not related to hemolysis or Gilbert's disease, ALT or AST
> 2 X ULN.
- Serum creatinine > 2.0 mg/dL or calculated creatinine clearance < 60 ml/min/1.73 m^2.
- Ascites requiring active medical management including paracentesis, or hyponatremia
(defined as serum sodium value of <134 Meq/L).
- Women patients who are pregnant or lactating; Male patients with female sexual
partners who are unwilling to follow the strict contraception requirements described
in this protocol; Patients who do not agree to use adequate contraceptive [including
prescription oral contraceptives (birth control pills), contraceptive injections,
intrauterine device (IUD), double-barrier method (spermicidal jelly or foam with
condoms or diaphragm), contraceptive patch, or surgical sterilization] before entry
and throughout the study; Female patients with reproductive potential who do not have
a negative serum beta-HCG pregnancy test at screening.
- Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na
- Uncontrolled hypertension (defined as a systolic pressure equal to or greater than 160
mmHg and/or a diastolic pressure equal to or greater than 110 mmHg).
- New onset seizures (within 3 months prior to the first dose of ON 01910.Na) or poorly
- Any concurrent investigational agent or chemotherapy, radiotherapy or immunotherapy.
- Treatment with standard MDS therapies or investigational therapy within 4 weeks of
starting ON 01910.Na.
- Psychiatric illness/social situations that would limit the patient's ability to
tolerate and/or comply with study requirements.
drug: ON 01910.Na
drug: ON 01910.Na
School of Medicine
300 Pasteur Drive
Stanford, CA 94305